Friedman, C. F., Spencer, C., Cabanski, C. R., Panageas, K. S., Wells, D. K., Ribas, A., Tawbi, H., Tsai, K., Postow, M., Shoushtari, A., Chapman, P., Karakunnel, J., Bucktrout, S., Gherardini, P., Hollmann, T. J., Chen, R. O., Callahan, M., LaVallee, T., Ibrahim, R., & Wolchok, J. (2022). ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Journal for immunotherapy of cancer, 10(1), . http://access.bl.uk/ark:/81055/vdc_100150524100.0x00000c